title: Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models.
abstract: BACKGROUND
  The rexinoid bexarotene (LGD1069, Targretin) is a highly selective retinoid x receptor (RXR) agonist that inhibits the growth of pre-malignant and malignant breast cells. Bexarotene was shown to suppress the development of breast cancer in transgenic mice models without side effects. The chemopreventive effects of bexarotene are due to transcriptional modulation of cell proliferation, differentiation and apoptosis. Our goal in the present study was to obtain a profile of the genes modulated by bexarotene on mammary gland from three transgenic mouse mammary cancer models in an effort to elucidate its molecular mechanism of action and for the identification of biomarkers of effectiveness.
  
  
  METHODS
  Serial analysis of gene expression (SAGE) was employed to profile the transcriptome of p53-null, MMTV-ErbB2, and C3(1)-SV40 mammary cells obtained from mice treated with bexarotene and their corresponding controls.
  
  
  RESULTS
  This resulted in a dataset of approximately 360,000 transcript tags representing over 20,000 mRNAs from a total of 6 different SAGE libraries. Analysis of gene expression changes induced by bexarotene in mammary gland revealed that 89 genes were dysregulated among the three transgenic mouse mammary models. From these, 9 genes were common to the three models studied.
  
  
  CONCLUSIONS
  Analysis of the indicated core of transcripts and protein-protein interactions of this commonly modulated genes indicate two functional modules significantly affected by rexinoid bexarotene related to protein biosynthesis and bioenergetics signatures, in addition to the targeting of cancer-causing genes related with cell proliferation, differentiation and apoptosis.
authors.affiliation: Department of Carcinogenesis, The University of Texas M,D, Anderson Cancer Center, Science Park-Research Division, Smithville, 78957, TX, USA. mabba777@hotmail.com
authors.forename: Martin C
authors.initials: MC
authors.lastname: Abba
authors.forename: Yuhui
authors.initials: Y
authors.lastname: Hu
authors.forename: Carla C
authors.initials: CC
authors.lastname: Levy
authors.forename: Sally
authors.initials: S
authors.lastname: Gaddis
authors.forename: Frances S
authors.initials: FS
authors.lastname: Kittrell
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jamal
authors.initials: J
authors.lastname: Hill
authors.forename: Reid P
authors.initials: RP
authors.lastname: Bissonnette
authors.forename: Daniel
authors.initials: D
authors.lastname: Medina
authors.forename: Powel H
authors.initials: PH
authors.lastname: Brown
authors.forename: C M
authors.initials: CM
authors.lastname: Aldaz
references.citation: J Exp Ther Oncol. 2005;5(2):133-43
references.pmid: 16471039
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13892-7
references.pmid: 14623968
references.citation: Breast Cancer Res. 2004;6(5):R499-513
references.pmid: 15318932
references.citation: Genome Biol. 2003;4(5):P3
references.pmid: 12734009
references.citation: Cancer Res. 2001 Aug 1;61(15):5697-702
references.pmid: 11479200
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14976-81
references.pmid: 12399545
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74
references.pmid: 12010861
references.citation: Cancer Res. 2000 Nov 1;60(21):5977-83
references.pmid: 11085516
references.citation: J Biol Chem. 2006 Jan 13;281(2):977-81
references.pmid: 16263703
references.citation: Science. 1997 May 23;276(5316):1268-72
references.pmid: 9157888
references.citation: J Biol Chem. 2003 Jul 11;278(28):25752-7
references.pmid: 12730199
references.citation: Cancer Res. 2006 Dec 15;66(24):12009-18
references.pmid: 17178900
references.citation: Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
references.pmid: 1359541
references.citation: Biochem J. 2004 Feb 15;378(Pt 1):17-20
references.pmid: 14683524
references.citation: Cancer Res. 1999 Nov 1;59(21):5464-70
references.pmid: 10554019
references.citation: Cancer Res. 2002 Nov 15;62(22):6376-80
references.pmid: 12438218
references.citation: Nat Rev Cancer. 2006 Jul;6(7):493-505
references.pmid: 16794633
references.citation: Breast Cancer Res. 2005;7(5):R737-44
references.pmid: 16168119
references.citation: Cancer Res. 2005 Aug 15;65(16):7378-85
references.pmid: 16103090
references.citation: Nat Cell Biol. 2001 Apr;3(4):E95-8
references.pmid: 11283628
references.citation: Nucleic Acids Res. 2005 Jan 1;33(Database issue):D433-7
references.pmid: 15608232
references.citation: Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):511-6
references.pmid: 9892664
references.citation: Cancer Res. 2004 Nov 1;64(21):7748-55
references.pmid: 15520179
references.citation: Int J Cancer. 2000 Nov 1;88(3):392-400
references.pmid: 11054668
references.citation: J Biol Chem. 2000 Mar 10;275(10):7087-94
references.pmid: 10702275
references.citation: Mutat Res. 2005 Aug 25;576(1-2):93-110
references.pmid: 15888345
references.citation: Mol Cell Biochem. 1999 Sep;199(1-2):41-8
references.pmid: 10544950
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7
references.pmid: 15840712
references.citation: Br J Cancer. 1998 Sep;78(6):701-9
references.pmid: 9743287
references.citation: Oncogene. 2000 Feb 21;19(8):1052-8
references.pmid: 10713689
references.citation: Oncogene. 2002 Sep 12;21(41):6366-76
references.pmid: 12214277
references.citation: Genome Res. 1997 Oct;7(10):986-95
references.pmid: 9331369
references.citation: Eur J Cancer Clin Oncol. 1989 Feb;25(2):243-50
references.pmid: 2702979
references.citation: EMBO J. 1998 May 1;17(9):2526-33
references.pmid: 9564035
references.citation: Biochem Biophys Res Commun. 1999 Apr 21;257(3):865-70
references.pmid: 10208875
references.citation: Cancer Res. 2001 Nov 1;61(21):7878-81
references.pmid: 11691807
references.citation: BMC Cancer. 2006 Jul 12;6:186
references.pmid: 16836752
references.citation: J Steroid Biochem Mol Biol. 1998 Dec;67(5-6):391-402
references.pmid: 10030688
references.citation: Clin Cancer Res. 2004 Jul 1;10(13):4427-36
references.pmid: 15240533
references.citation: Genome Biol. 2003;4(10):R70
references.pmid: 14519205
references.citation: Leukemia. 1994 Nov;8(11):1797-806
references.pmid: 7967725
references.citation: Bioinformatics. 2003 Nov 1;19(16):2065-71
references.pmid: 14594711
references.citation: Biochem J. 2003 Feb 15;370(Pt 1):195-203
references.pmid: 12429024
references.citation: Cancer Biol Ther. 2005 Sep;4(9):918-23
references.pmid: 16103750
references.citation: Carcinogenesis. 2005 Dec;26(12):2095-104
references.pmid: 16033770
references.citation: Nucleic Acids Res. 2007 Jan;35(Database issue):D358-62
references.pmid: 17098935
references.citation: Int J Cancer. 1999 Jun 11;81(6):923-9
references.pmid: 10362140
references.citation: Oncogene. 2000 Feb 21;19(8):1020-7
references.pmid: 10713685
references.citation: J Biol Regul Homeost Agents. 2003 Jan-Mar;17(1):1-12
references.pmid: 12757018
references.citation: CA Cancer J Clin. 2006 May-Jun;56(3):168-83
references.pmid: 16737949
references.citation: Science. 1956 Feb 24;123(3191):309-14
references.pmid: 13298683
references.citation: Clin Cancer Res. 2003 Jul;9(7):2567-75
references.pmid: 12855632